There is ongoing research on antibiotic use, the microbiome and it’s impact on our health. This website will try to include up-to-date articles and research on these topics and related topics. If you know of an article or research that you believe should be included on this website please contact us below.
Rodney Dietert, PhD
Dr. Dietert is a Professor in the Department of Microbiology and Immunology. He received the BS degree in Zoology from Duke University in 1974 and his PhD from University of Texas at Austin in 1977. Dr. Dietert has been: Director of Graduate Studies for the Graduate Field of Immunology, Senior Fellow in the Center for the Environment, Director of the Institute for Comparative and Environmental Toxicology, Director of the Program on Breast Cancer and Environmental Risk Factors and President of the Immunotoxicology Specialty Section of the Society of Toxicology. His research on the immune programming and the developmental basis of childhood and adult disease has been supported by the NSF, the USDA, the NIH and industry.
Dr. Dietert’s research and public health interests concern risk reduction for noncommunicable diseases (also known as chronic diseases). The initiatives include: 1) microbiome-based strategies for self-completion of the infant and microbiome management for improved later-life health, 2) determination of immunological risk in early life from environmental chemicals, foods, and drugs, 3) identification and prevention of co-morbid, noncommunicable diseases, and 4) integrated approaches to reduce the risk of noncommunicable diseases.
This website is a resource for those interested in the growing epidemic facing our communities. Research experts listed on this website are not liable for any content on this website. We have simply listed them so that the public is aware of the great research being done to address modern epidemics. Please come back to the site often as we grow our resources.
Martha Carlin
Martha began her career with Arthur Andersen after graduating with honors from the University of Kentucky with a degree in accounting. Her early training at Andersen included a process called “transaction flow revenue” which built her foundation in complex systems thinking. This process follows the flow of transactions in a business to identify weak points and systemic risk. Martha continued to apply this systems-based thinking throughout her career and life, to solve complex problems in new ways .
Martha spent more than twenty years in business consulting and real estate operations for two of the largest real estate investment trusts in the US, becoming an expert in business turnarounds and systems-based solutions to improve operations. locked0 L
In 2002, her young husband was diagnosed with Parkinson’s diseas and Martha began to apply her turnaround skills to the task of understanding this complex disease. Martha is a self-taught scientist who studied across many subjects including plant and soils biology, nutrition, chemistry, molecular biology, infectious disease, genetics, epigenetics, proteins, neuroscience and many others in search of something beyond point solutions to approach complex disease.
In 2015, Martha began to dedicate her full attention to the turnaround of chronic disease, including Parkinson’s, funding research at the University of Chicago with Dr. Jack Gilbert to build a metagenomic time series set of data.
Later that year, Martha and Jack founded The BioCollective, LLC along with Dr. Suzanne Vernon, formerly of the CDC, to build an innovation engine for pattern recognition across the population and to accelerate product development for microbiome products. Since founding the company they have built a sample base of subjects age 1 to 102 across various health states, isolated and cultured more than 250 new strains of bacteria for product development, and developed AI tools and metabolic modeling to identify patterns in disease and enable rapid product development. They have filed patents for targeted therapeutics as well as methods of collection and their unique BioCollector™. Their BioFlux™ Metabolic Model has enabled the rapid proto-typing of products targeting glucose metabolism, antibiotic resistance, sleep, TCA cycle/energy metabolism and others. The company is privately funded by Carlin and small group of private investors.
This website is a resource for those interested in the growing epidemic facing our communities. Research experts listed on this website are not liable for any content on this website. We have simply listed them so that the public is aware of the great research being done to address modern epidemics. Please come back to the site often as we grow our resources.
Martin J. Blaser, MD
Dr. Blaser’s studies focus on bacteria of the human microbiome including Campylobacter and Helicobacter species that live in the mucus layer overlying the mucosal epithelium of mammals, including humans. At the lab in NYU they explore the biology of colonization and the nature of the interactions that lead to (or protect from) disease. For the normal microbiome, they study how early life perturbations affect host developmental phenotypes. On-going work focuses on the metabolic syndrome, and specifically on obesity and type 2 diabetes, as well as inflammatory disorders such as type 1 diabetes, asthma, psoriasis, and skin infections.
This website is a resource for those interested in the growing epidemic facing our communities. Research experts listed on this website are not liable for any content on this website. We have simply listed them so that the public is aware of the great research being done to address modern epidemics. Please come back to the site often as we grow our resources.